Ethypharm is a specialty pharmaceutical company with European roots, focused on specific Central Nervous System (CNS) diseases and conditions, and on adding value to medicines used in Critical Care situations.
Discover Ethypharm at a glance
Many of our products are indicated for sensitive situations in which patients either suffer from debilitating conditions such as chronic pain or addiction, or are in a critical state.
All around the world, Ethypharm employees are engaged daily to make the difference for patients’ lives by ensuring that people in need are able to receive the right treatment at the right time and with the right support.
Ethypharm is deeply engaged in the CNS and Critical Care areas, where our medicines treat patients today and our teams work on innovative solutions for tomorrow. Willing to grow beyond our recognised positions in the treatment of severe pain and opioid dependency, we are constantly screening opportunities in search for those which will respond to unmet needs in our 2 core therapeutic areas.
Ethypharm is a rapidly transforming company, with a clear strategy and significant growth ambition. Our teams are constantly looking for opportunities to develop our product portfolio, selectively enlarge our geographical coverage and enrich our development pipeline. We are extremely open to discussing potential partnerships. Get to know our R&D and business development (BD) teams and come discuss with us!
Hélène Moore appointed Head of Ethypharm Digital Therapy with responsibility for building a European Leader in this innovative field.
On May 6th, 2021 – One month after the acquisition of the exclusive rights for two innovative digital therapies in the Central Nervous System, deprexis® and vorvida®, Ethypharm announced the establishment of a new business unit, Ethypharm Digital Therapy SAS, and the appointment of Hélène Moore as Executive Vice-President (EVP) and Head of the entity.
Read the full press release in our newsroom
NB: By clicking on this link, you will be redirected to an external website
Ethypharm establishes direct presence in Italy
On April 23, 2021 Ethypharm announced that it now has a fully established affiliate to operate directly in Italy, the third largest pharmaceutical market in Europe. Under the leadership of Bruno Rago, Ethypharm Italy will reinforce the Group’s commercial footprint in Europe, notably in its core therapeutic area of the Central Nervous System.
Read the full press release in our newsroom
NB: By clicking on this link, you will be redirected to an external website
Ethypharm is growing fast and is always looking to enrich its teams with new talented individuals. We encourage you to visit this site regularly and to follow Ethypharm on LinkedIn to read our latest updates and stay informed about our job opportunities.
Linked